Gene Therapy Market Size, Share & Industry Analysis by Product (Zolgensma, Luxturna, Roctavian, and Others), By Vector Type (Viral Vectors and Non-Viral Vectors), By Indication (Genetic Disorders, Ophthalmology, Hematology, and Others), By End User (Hospitals & Clinics, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2024

Estimated Year

2025

Forecast Period

2025-2032

Historical Period

2019-2023

Growth Rate

CAGR of 18.21% from 2025-2032

Unit

Value (USD Million)

Segmentation

By Product

·         Zolgensma

·         Luxturna

·         Roctavian

·         Others

By  Vector Product

·         Viral Vectors

·         Non-Viral Vectors

By  Indication

·         Genetic Disorders

·         Ophthalmology

·         Hematology

·         Others

By  End User

·         Hospitals & Clinics

·         Specialty Clinics

·         Others

By Geography

·         North America (By Product, Vector Type, Indication, End User, and Country)

o   U.S.

o   Canada

·         Europe (By Product, Vector Type, Indication, End User, and Country/Sub-region)

o   Germany

o   U.K.

o   France

o   Spain

o   Italy

o   Scandinavia

o   Rest of Europe

·         Asia Pacific (By Product, Vector Type, Indication, End User, and Country/Sub-region)

o   China

o   Japan

o   India

o   Australia

o   Southeast Asia

o   Rest of Asia Pacific

·         Latin America (By Product, Vector Type, Indication, End User, and Country/Sub-region)

o   Brazil

o   Mexico

o   Rest of Latin America

·         Middle East & Africa (By Product, Vector Type, Indication, End User, and Country/Sub-region)

o   GCC

o   South Africa

·         Rest of the Middle East & Africa